Drug Profile
Anti-HER2 small molecule imaging agent - Affibody
Alternative Names: [111In]ABY-025; [68Ga]ABY-025; ABY-002; ABY-025; ABY0125; Anti-HER2 AffibodyLatest Information Update: 06 Dec 2022
Price :
$50
*
At a glance
- Originator Affibody; GE Healthcare
- Developer Affibody; Biomedical Radiation Sciences; Herlev Hospital; Swedish Cancer Society
- Class Peptide fragments; Small molecules
- Mechanism of Action Diagnostic imaging enhancers; Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III HER2 positive breast cancer
- Preclinical Gastric cancer; Non-small cell lung cancer; Oesophageal cancer
Most Recent Events
- 06 Dec 2022 Preclinical trials in Gastric cancer (Diagnosis) in Sweden (IV), prior to December 2022 (Affibody Pipeline, December 2022)
- 06 Dec 2022 Preclinical trials in Non-small cell lung cancer (Diagnosis) in Sweden (IV), prior to December 2022 (Affibody Pipeline, December 2022)
- 06 Dec 2022 Preclinical trials in Oesophageal cancer (Diagnosis) in Sweden (IV), prior to December 2022 (Affibody Pipeline, December 2022)